04:45 PM EST - Tekmira Pharmaceuticals Corporation : announced the results of its Phase I clinical trial with TKM-PLK1, an RNAi therapeutic for the treatment of solid tumors. Tekmira Pharmaceuticals Corporation
shares T.TKM are trading down $0.35 at $4.55.
